NCT07225426Active, not recruiting
Personalizing Financial Incentives
Log2LoseAI: Reinforcement Learning to Create a Framework for Personalizing Financial Incentives
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to determine the feasibility of providing personalized incentives for dietary self-monitoring and/or interim weight loss to people enrolled in a weight-loss program
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 94 (actual)
- First submitted
- 4 Nov 2025
- Start date
- 4 Feb 2026
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- University of Utah
- Diseases
- Obesity
- NCT number
- NCT07225426
What you commit to
- Study type: Interventional
- Participants enrolled: 94
- From 4 Feb 2026 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Weight loss of at least 10lbs in the month prior to screening
- Currently enrolled or enrolled in the previous month in a clinical, research, or community program focusing on lifestyle change that could affect weight
- New user of weight loss medication
- Unstable heart disease in the 6 months prior to screening
Other illness
- History of bariatric procedure or planning to have bariatric procedure in the study timeframe
- Significant dementia, drug or alcohol abuse, or unstable psychiatric illness (e.g., schizophrenia, psychosis)
- Current treatment for cancer or being treated for cancer (besides basal cell carcinoma or squamous cell) in the last 6 months
- Chronic kidney disease at stage 4 or higher
- Pain, fainting, or other conditions that prohibit mild/moderate exercise
- History of ascites requiring paracentesis
Lab values
- Diuretic medication doses higher than hydrochlorothiazide or chlorthalidone 25 mg daily, furosemide 40 mg daily, torsemide 20 mg daily, bumetanide 1 mg daily, or any use of metolazone; use of potassium-sparing diuretics is acceptable
Other
- Weight \> 380lbs
- Pregnant, lactating or planning on becoming pregnant during the study
- Residing in a nursing home, skilled nursing facility or assisted living facility
- Impaired hearing
- Use of insulin, sulfonylureas, or meglitinides due to increased risk for hypoglycemia
- Exertional chest pain
- Inducing vomiting to prevent weight gain or counteract the effects of eating an average of 1 time per week or more in the past 3 months\*
- Not suitable for study participation due to other reasons at the discretion of the investigators
Who the study is looking for
- Willing to attend virtual baseline and follow-up data collection visits
- At least 18 years of age
- Verified obesity as defined as a BMI ≥30 kg/m2
- Agree to attend 13 biweekly group classes (virtual) delivered by a registered dietitian
- Agree to review study materials between classes
- Regular access to an unshared smart phone
- Reliable access to internet
- Able to speak and read English
- Desire to lose weight
- Able to connect to a video conference call using a smartphone, tablet or computer with a webcam and microphone
- Ability to download and use Fitbit app daily
- Have or be willing to create a Gmail address
- Physical ability to stand on a scale without support
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Utah Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.